Welcome to our dedicated page for Jade Biosciences SEC filings (Ticker: JBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jade Biosciences filings document a Nasdaq-listed clinical-stage biotechnology issuer developing antibody therapies for autoimmune diseases. Form 8-K reports furnish operating and financial results and attach corporate updates covering JADE101, JADE201, JADE301, research progress, and liquidity-related disclosures.
The company's proxy and material-event filings cover annual meeting matters, board and officer changes, compensatory arrangements, employment inducement stock plans, material agreements, private placement securities, common stock and pre-funded warrant terms, and other capital-structure disclosures. The filings also identify Jade as an emerging growth company with common stock registered under the Exchange Act.
Jade Biosciences, Inc. has a significant shareholder group led by Venrock Healthcare funds that, together with related entities and individuals Nimish Shah and Bong Koh, reports beneficial ownership of 5,145,330 shares of common stock (including shares issuable upon exercise of pre-funded warrants) as of June 30, 2026, representing 8.3% of the common stock. The holdings comprise 570,656 shares and pre-funded warrants for up to 358,450 shares held by VHCP III, 57,017 shares and pre-funded warrants for up to 35,825 shares held by VHCP Co-Investment III, and 2,592,691 shares and pre-funded warrants for up to 1,530,691 shares held by VHCP EG. The percentage ownership is calculated using 49,359,875 shares outstanding as of May 1, 2026 plus additional shares issued and shares underlying pre-funded warrants.
Bellevue Group AG and its wholly owned subsidiary Bellevue Asset Management AG, both organized in Switzerland, report their beneficial ownership in Jade Biosciences, Inc. common stock in this amended filing. The securities class is common stock of Jade Biosciences, Inc., CUSIP 008064206.
The reporting persons state beneficial ownership of 3,057,996 shares of common stock, representing 5.0% of the class. They report 0 shares with sole voting or dispositive power and 3,057,996 shares with shared voting and shared dispositive power. The percentage is based on 60,845,967 shares of common stock outstanding as of June 5, 2026, after an equity offering by Jade Biosciences, as referenced in the company’s prospectus supplement filed June 4, 2026 and press release dated June 5, 2026. The statement is filed jointly by Bellevue and Bellevue Asset Management AG as a parent holding company and its subsidiary.
Jade Biosciences, Inc. reported a larger net loss as it invested heavily in its autoimmune biologics pipeline. For the three and six months ended June 30, 2026, net loss was $55.8 million and $96.1 million, compared to $32.1 million and $70.3 million in the prior-year periods. Operating expenses more than doubled year over year to $58.9 million for the quarter, driven mainly by higher research and development spending and stock-based compensation.
Cash and cash equivalents were $107.2 million and investments were $354.0 million, for total liquid resources of $461.2 million as of June 30, 2026. Management states this is sufficient to fund planned operating and capital needs for at least twelve months from the financial statement issuance date. Net cash used in operating activities was $67.7 million for the first half of 2026, while financing activities provided $192.7 million, including $162.1 million net from a June 2026 equity financing and $29.3 million from at-the-market share sales.
The company advanced its programs JADE101, JADE201, and JADE301. Positive interim Phase 1 data for JADE101 in healthy volunteers showed approximately 70% IgA reductions sustained at 12 weeks at a 700 mg subcutaneous dose, supporting potential every-12-week dosing in IgA nephropathy. Multiple milestone and royalty-bearing license agreements with Paragon and manufacturing arrangements with WuXi Biologics continue to structure future development and commercialization economics.
Jade Biosciences, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases, reported results for the quarter ended June 30, 2026 and provided a pipeline update. The company highlighted positive interim Phase 1 data for JADE101 in IgA nephropathy, noting biomarker activity and durability with a favorable safety profile. JADE301, an anti-IFN-ß monoclonal antibody for dermatomyositis, is being advanced toward Phase 1 initiation, while JADE201 continues clinical progress in autoimmune diseases.
Cash, cash equivalents and investments were $461,205 thousand as of June 30, 2026, compared with $336,158 thousand at December 31, 2025. Total liabilities were $32,198 thousand and stockholders’ equity was $439,915 thousand. For the second quarter of 2026, research and development expense was $50,065 thousand and general and administrative expense was $8,851 thousand, leading to total operating expenses of $58,916 thousand versus $27,778 thousand a year earlier. Net loss for the quarter was $55,765 thousand compared with $32,134 thousand in the prior-year period, with net loss per share attributable to common stockholders of $0.76 versus $0.86.
Jade Biosciences, Inc. has a new large shareholder group reported on a Schedule 13G. Paradigm BioCapital Advisors LP, its general partner Paradigm BioCapital Advisors GP LLC, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd. together report beneficial ownership of shares of Jade Biosciences common stock.
The Adviser, its general partner, and Senai Asefaw each report 3,106,793 shares of common stock, representing 5.1% of the class, with sole voting and dispositive power over those shares. Paradigm BioCapital International Fund Ltd. separately reports 2,738,259 shares, or 4.5% of the class, also with sole voting and dispositive power. Percentages are based on 60,845,967 shares of common stock outstanding as of June 5, 2026, after an equity offering. Each reporting person disclaims beneficial ownership of any shares other than those directly owned.
Jade Biosciences reported that Janus Henderson Group Ltd. is the beneficial owner of 6,273,262 shares of common stock, representing 10.6% of the class as of 06/30/2026. The filing states the position reflects shared voting power and shared dispositive power over those shares.
The filing describes Janus Henderson as the ultimate parent of multiple registered asset managers that exercise investment and voting discretion on behalf of client accounts (the "Managed Portfolios"). The Asset Managers disclaim rights to receive dividends or sale proceeds from those Managed Portfolios; the filing notes no individual Managed Portfolio owns more than five percent of the class.
Jade Biosciences entered a JADE301 License Agreement with Paragon Therapeutics, securing a royalty-bearing, worldwide, exclusive, sublicensable license to certain monospecific antibodies against an undisclosed target for use across all human therapeutic areas.
The company may pay Paragon up to $22.0 million in development and regulatory milestones, including a $1.5 million development candidate nomination fee paid in January 2026 and a further $2.5 million on first dosing of a human in a Phase 1 trial.
On a product-by-product basis, Jade could owe up to approximately $20.1 million in sublicensing fees, plus low to mid-single-digit royalties on annual net sales of monospecific products and mid-single-digit royalties on multispecific products, with a 30% royalty reduction where no valid patent exists and royalties lasting at least 12 years from first sale or until patent expiry.
Paragon agrees not to start new campaigns for monospecific antibodies to the same target in the field for five years, and the agreement can be terminated on 60 days’ notice, for uncured material breach, or, where allowed by law, upon a party’s insolvency or bankruptcy.
Jade Biosciences, Inc. director Mark Eisner reported receiving a stock option grant that gives him the right to buy 47,675 shares of common stock at an exercise price of $21.81 per share. All 47,675 option shares were reported as held directly after the grant.
The option expires on June 24, 2036. According to the footnote, 1/36 of the total option shares vest monthly after the grant date, as long as Eisner continues to provide service to the company on each vesting date. This structure turns the award into ongoing, service-based compensation rather than an immediate, fully vested position.
Jade Biosciences, Inc. director Mark Eisner filed an initial Form 3, which is a statement of beneficial ownership for company insiders. This filing lists him as a director but does not report any buy, sell, or derivative transactions, indicating it is purely an initial ownership disclosure at this time.
Jade Biosciences, Inc. filed an 8-K announcing that its Board appointed Mark Eisner, M.D., M.P.H., as a Class I director effective June 25, 2026. He will serve until the 2028 annual meeting and join the Nominating and Corporate Governance Committee.
Dr. Eisner brings more than 25 years of leadership in clinical development and immunology, including senior roles at Vir Biotechnology, Sonoma Biotherapeutics, FibroGen and Genentech/Roche, as well as an academic career at UCSF. In connection with his appointment, he received a stock option to purchase 47,675 shares of Jade common stock under the 2025 Stock Incentive Plan, vesting in equal monthly installments over three years and accelerating upon a change in control, subject to continued service. He will also participate in the standard non-employee director compensation program and sign the company’s standard indemnification agreement. The company issued a press release with these details.